Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals Q2 2023 Earnings Report

Day One Biopharmaceuticals logo
$7.19 +0.19 (+2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$7.18 -0.01 (-0.14%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals EPS Results

Actual EPS
-$0.61
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Day One Biopharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, July 29, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Day One Biopharmaceuticals Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN) (NASDAQ:DAWN) is a clinical-stage biotechnology company dedicated to developing precision therapies for patients with solid tumors. The company’s research focuses on designing small molecules that target key drivers of cancer growth and survival, including hormone receptors and cell cycle regulators. Its lead candidate, camizestrant, is an oral selective estrogen receptor degrader (SERD) currently in late-stage development for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer.

Beyond its lead program, Day One leverages a proprietary discovery platform to advance additional candidates across multiple oncology targets. Early-stage assets include novel molecules aimed at disrupting oncogenic signaling and DNA damage repair pathways. The company’s pipeline strategy emphasizes differentiated mechanisms of action designed to address areas of high unmet medical need and to overcome resistance to existing therapies.

Founded in 2018 and headquartered in San Francisco, Day One Biopharmaceuticals completed its initial public offering in mid-2021. The company maintains research operations in San Diego and supports clinical development through collaboration with trial sites across North America and Europe. This geographic footprint enables Day One to enroll a diverse patient population and to expedite regulatory interactions with health authorities in key markets.

Day One’s leadership team is led by Chief Executive Officer David Meek, a seasoned biotech executive with more than two decades of experience in oncology drug development and commercialization. The management team also includes veterans from leading pharmaceutical and biotechnology companies, bringing deep expertise in clinical operations, regulatory affairs, and global commercial planning. Under this guidance, Day One is positioned to advance its pipeline toward potential regulatory approval and to deliver new treatment options for cancer patients.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat